KW
Johnson & Johnson Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Stelara (ustekinumab) | Psoriasis, Crohn's Disease, Ulcerative Colitis | Approved |
| Darzalex (daratumumab) | Multiple Myeloma | Approved |
| Imbruvica (ibrutinib) | Blood Cancers | Approved |
| Tremfya (guselkumab) | Psoriasis, Psoriatic Arthritis | Approved |
| Erleada (apalutamide) | Prostate Cancer | Approved |
| JNJ-4528 (CAR-T) | Multiple Myeloma | Phase 3 |
| JNJ-6372 | Lung Cancer | Phase 2 |
| Nipocalimab | Myasthenia Gravis | Phase 3 |
Leadership Team at Johnson & Johnson
JD
Joaquin Duato
Chief Executive Officer
JW
Joseph Wolk
Chief Financial Officer
PS
Paul Stoffels
Chief Scientific Officer
JT
Jennifer Taubert
Worldwide Chairman, Pharmaceuticals
AM
Ashley McEvoy
Worldwide Chairman, Medical Devices
PF
Peter Fasolo
Chief Human Resources Officer
MU
Michael Ullmann
General Counsel
MM
Mathai Mammen
Global Head, Janssen Research & Development
JR
John Reed
Former Global Head of R&D